Authors

Edward B. Garon, MD, David Geffen School of Medicine at UCLA

Edward B. Garon, MD, MS

Latest:

Key Takeaways and Closing Thoughts on ADCs

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Edward Bradley, MD

Latest:

Dr. Bradley on OX40 for the Treatment of Cancer

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Edward Garon, MD

Latest:

Dr Garon on Considerations for Perioperative Immunotherapy Use in Lung Cancer

Edward B. Garon, MD, MS, discusses key considerations when selecting an optimal perioperative treatment approach for patients with lung cancer.

Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA

Latest:

Managing Toxicities in Short- and Long-Term Treatment with ADCs

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Edward Kim, MD, Levine Cancer Institute, Atrium Health

Edward Kim, MD, University of California Davis

Edward P. Ambinder, MD

Latest:

More Progress Needed to Bring Oncology Practice Into the Digital Health Age

Much needs to be done to improve interoperability of medical data systems. However, standards and new systems are developing at a rapid pace, affording advantages and efficiencies where, previously, enormous impediments stood in the way.

Edward S. Kim, MD

Latest:

Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Edward S. Kim, MD, FACP, Carolinas HealthCare System

Edward S. Kim, MD, Levine Cancer Institute

Edwin M. Posadas, MD

Latest:

Recent Progress in the Prostate Cancer Treatment Landscape

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center

Latest:

Practical Application of PARP Inhibitors in Metastatic CRPC

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Ehab Atallah, MD, Medical College of Wisconsin

Latest:

Emerging Agents for R/R CLL

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Eileen Connolly, MD, PhD

Latest:

Dr. Connolly on Potential Benefit of Postmastectomy Radiation for Breast Cancer

Eileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.

Eileen Koutnik-Fotopoulos

Latest:

Celebrating Life and Liberty: 3rd Annual Survivorship Event

With the Statue of Liberty as a symbolic backdrop, nearly 2200 cancer patients, caregivers, and healthcare professionals recently gathered at the 3rd Annual 'Celebrating Life and Liberty' survivorship event.

Eileen M. O

Eileen M. Oâ€™Reilly, MD

Latest:

PALB2 Mutations Confer Susceptibility to Familial Pancreatic Cancer and May Provide a Novel Targeted Therapeutic Approach to Cancer

Germline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.

Eileen M. O'Reilly, MD

Latest:

Dr. O'Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic Cancer

Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Eileen M. O'Reilly, MD, Memorial Sloan Kettering Cancer Center